📊 CVM Key Takeaways
Is Cel Sci Corp. (CVM) a Good Investment?
CEL SCI CORP faces an acute financial crisis with negative revenue, mounting losses, and critical liquidity distress. Operating cash burn of $8.0M annually against only $1.9M in cash reserves creates an immediate solvency threat. The company cannot service its debt or operations, with current ratio of 0.60x and interest coverage of -52.2x indicating imminent default risk.
CEL SCI CORP's fundamentals remain very weak: the business is generating essentially no meaningful revenue, while operating losses and negative free cash flow continue to consume capital. Although liquidity is still adequate in the near term, persistent losses, weak coverage of debt obligations, and dependence on external funding materially weaken the quality of the financial profile.
Cel Sci Corp. Key Strengths (CVM)
- Moderate debt-to-equity ratio of 0.83x provides some theoretical leverage capacity
- Total assets of $17.7M represent potential liquidation value
- YoY improvements in loss metrics, though from deeply negative base
- Current ratio of 1.39x and cash balance of $6.28M provide some near-term liquidity support
- Debt/equity of 0.51x is not extreme relative to equity base
- Asset base of $22.89M exceeds total liabilities of $11.76M, leaving positive book equity
CVM Stock Risks: Cel Sci Corp. Investment Risks
- Negative revenue of -205.3K indicates fundamental operational failure or accounting anomalies
- Critical liquidity crisis: current ratio 0.60x and quick ratio 0.39x signal inability to meet short-term obligations
- Severe cash burn: -$8.0M operating cash flow against only $1.9M cash reserves (less than 3 months runway)
- Cannot service debt: interest coverage ratio of -52.2x shows operating income insufficient to cover interest
- Negative returns: ROE -159.1% and ROA -61.8% destroying shareholder value
- Long-term debt of $5.7M with no operational cash flow to support repayment
- Revenue base is negligible and does not support the operating cost structure
- Net loss of $5.47M and operating cash outflow of $4.02M indicate ongoing cash burn
- Negative interest coverage and weak profitability ratios suggest limited financial flexibility if losses persist
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to insolvency
- Operating cash flow turnaround timing
- Revenue stabilization and path to profitability
- Debt restructuring, refinancing announcements, or capital raise activity
- Quarterly operating cash burn relative to cash on hand
- Revenue commercialization progress and trend in operating losses
Cel Sci Corp. (CVM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 3,918.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
CVM Profit Margin, ROE & Profitability Analysis
CVM vs Healthcare Sector: How Cel Sci Corp. Compares
How Cel Sci Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cel Sci Corp. Stock Overvalued? CVM Valuation Analysis 2026
Based on fundamental analysis, Cel Sci Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cel Sci Corp. Balance Sheet: CVM Debt, Cash & Liquidity
CVM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cel Sci Corp.'s revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-15.31 indicates the company is currently unprofitable.
CVM Revenue Growth, EPS Growth & YoY Performance
CVM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2017 | $51.8K | -$3.8M | $-1.29 |
| Q2 2017 | $34.4K | -$4.9M | $-0.03 |
| Q3 2011 | $30.9K | -$601.1K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cel Sci Corp. Dividends, Buybacks & Capital Allocation
CVM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cel Sci Corp. (CIK: 0000725363)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVM
What is the AI rating for CVM?
Cel Sci Corp. (CVM) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVM's key strengths?
Claude: Moderate debt-to-equity ratio of 0.83x provides some theoretical leverage capacity. Total assets of $17.7M represent potential liquidation value. ChatGPT: Current ratio of 1.39x and cash balance of $6.28M provide some near-term liquidity support. Debt/equity of 0.51x is not extreme relative to equity base.
What are the risks of investing in CVM?
Claude: Negative revenue of -205.3K indicates fundamental operational failure or accounting anomalies. Critical liquidity crisis: current ratio 0.60x and quick ratio 0.39x signal inability to meet short-term obligations. ChatGPT: Revenue base is negligible and does not support the operating cost structure. Net loss of $5.47M and operating cash outflow of $4.02M indicate ongoing cash burn.
What is CVM's revenue and growth?
Cel Sci Corp. reported revenue of $-205.3K.
Does CVM pay dividends?
Cel Sci Corp. does not currently pay dividends.
Where can I find CVM SEC filings?
Official SEC filings for Cel Sci Corp. (CIK: 0000725363) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVM's EPS?
Cel Sci Corp. has a diluted EPS of $-1.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CVM's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cel Sci Corp. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CVM stock overvalued or undervalued?
Valuation metrics for CVM: ROE of -159.1% (sector avg: 15%), net margin of 5,327.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CVM's AI grade for 2026?
Our dual AI analysis gives Cel Sci Corp. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CVM's free cash flow?
Cel Sci Corp.'s operating cash flow is $-8.0M, with capital expenditures of $0.0. FCF margin is 3,918.9%.
How does CVM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 5,327.1% (avg: 12%), ROE -159.1% (avg: 15%), current ratio 0.60 (avg: 2).